The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed. The study ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial ...

Good day, ladies and gentlemen, and welcome to COMPASS Pathways' Second Quarter 2024 Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Investing.com - BTIG reiterated a Buy rating and $14.00 price target on Compass Pathways (NASDAQ:CMPS) on Wednesday, citing the company’s progress toward regulatory approval for its COMP360 treatment.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the ...